Analyst Ratings for Corcept Therapeutics (cort)
cort Rating Summary
cort Price Target Summary
- Highest: $11.00 (JMP Securities)
- Lowest: $2.00 (Piper Jaffray)
- Average: $6.00
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$6.00 (+231.5%)
Avg. $ Target:
$6.00 (+231.5%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/6/2013 | Piper Jaffray | Downgrade | Neutral (Overweight) |
2.00 (4.00) |
1.77 | 1.81 | 2.26% | Details |
| 1/3/2013 | Janney Montgomery Scott | New Coverage | Buy (N/A) |
3.00 (N/A) |
1.48 | 1.81 | 22.3% | Details |
| 12/10/2012 | Cowen | Downgrade | Neutral (Outperform) |
N/A (N/A) |
1.58 | 1.81 | 14.56% | Details |
| 11/2/2012 | Oppenheimer | Downgrade | Perform (Outperform) |
N/A (N/A) |
2.24 | 1.81 | -19.2% | Details |
| 7/13/2012 | BofA/Merrill Lynch | New Coverage | Underperform (N/A) |
4.00 (N/A) |
4.44 | 1.81 | -59.23% | Details |
| 6/29/2012 | ThinkEquity | New Coverage | Buy (N/A) |
7.00 (N/A) |
4.29 | 1.81 | -57.81% | Details |
| 6/8/2012 | Credit Suisse | New Coverage | Outperform (N/A) |
6.00 (N/A) |
4.06 | 1.81 | -55.42% | Details |
| 1/18/2012 | Leerink Swann » Updated 2/21/2012 |
Upgrade | Outperform (N/A) |
5.00 (N/A) |
3.12 | 1.81 | -41.99% | Details |
| 1/5/2012 | BioLogic Equity Research | New Coverage | Sell (N/A) |
N/A (N/A) |
3.44 | 1.81 | -47.38% | Details |
| 8/19/2010 | Global Hunter Securities | New Coverage | Buy (N/A) |
N/A (N/A) |
2.99 | 1.81 | -39.46% | Details |
